Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

biophysical properties. We will continue exploring its therapeutic potential to benefit patients worldwide." On January 10, 2025, Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech") entered into a global licensing...

Avanzanite Bioscience has appointed a new Chief Financial Officer

industry. Most recently, he served as CFO at Proteome Sciences plc and Paion AG where he successfully secured more than €150mln in financing and played a pivotal role in establishing key commercial infrastructure across Europe. Earlier in this...

HOOKIPA Pharma announces the completion of enrollment in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV

for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United...

Dipal Doshi has been elected to Azenta's Board of Directors

is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on...

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For...

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only...

Beacon Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for laru-zova (AGTC-501)

fully enrolled, Phase 2, randomized, controlled study evaluating the safety, efficacy and tolerability of laru-zova in 14 male patients with XLRP caused by mutations in the RPGR gene. The study's primary endpoint is the proportion of response by...

Lutris Pharma secures $30 million in financing to advance the development of a biopharmaceutical aimed at improving the effectiveness of anti-cancer drugs

cutaneous dose-limiting toxicity, announced that it has secured a $30 million financing to advance the development of LUT014, an innovative topically applied gel aimed at reducing EGFRi-induced rashes, a common adverse side effect of these...

Cellipont Bioservices and Secretome Therapeutics partner for cGMP manufacturing of the Master Cell Bank for their lead asset, STM-01

progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic's lead asset STM-01. Under this partnership, Cellipont Bioservices will provide technology transfer, analytical method transfer, and cGMP...

West introduces Daikyo PLASCAP® RUV closures in a new nested format at Pharmapack

This one-step press-fit solution for vial closure is offered in ready-to-use, validated formats compatible with vials with 13mm and 20 mm crowns. The new 6x8 nested tub configuration supports the West 10ml nested CZ vials as well as selected nested...

Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. These results confirm the strong Phase 1 and preclinical data package, underscoring the potential breadth and depth of Nck...

MalarVx licenses HDT Bio's repRNA/LION™ technology to develop a groundbreaking malaria vaccine

million cases in 2023, according to the World Health Organization. Despite the expenditure of $4 billion per year on control1, malaria deaths and cases have not substantively changed over the last decade. Consequently, a safe, effective,...

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T candidate to...

Next Generation Gene Therapeutics (NGGT) announces the publication of early clinical trial results for NGGT001, a treatment for Bietti's Crystalline Dystrophy (BCD)

with limited options and a bleak prognosis. This open-label, dose-escalation trial, conducted at two sites, involved 12 participants with genetically confirmed BCD. Participants received a single subretinal injection of either 1.5 e11 or 3.0e11...

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 100 published patent families.

NTx announces the full commercial availability of NTxscribe to broadly enable RNA therapies

RNA in continuous flow and can scale seamlessly from small research doses to commercial volumes. NTxscribe produces 10-50 mg of high integrity RNA in two hours, shortening timelines for bringing new therapies and vaccines to market and empowering...

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three...

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG...

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study was...

Long Island University alumnus Dr. Howard Murad '62 launches the Inclusive Wellness Initiative with the Arnold & Marie Schwartz College of Pharmacy and Health Sciences

Dr. Howard Murad, a 1962 graduate of Long Island University's Arnold & Marie Schwartz College of Pharmacy and Health Sciences and an internationally recognized innovator in the science of skin care, is establishing the Dr. Howard Murad '62...